OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas

Cancer Research

Volumn 70, Issue 1, 2010, Pages 181-191

  Adamson, David C ^a,b   Shi, Qun ^a   Wortham, Matthew ^a   Northcott, Paul A ^c   Di, Chunhui ^a   Duncan, Christopher G ^a   Li, Jianjun ^a   McLendon, Roger E ^a   Bigner, Darell D ^a   Taylor, Michael D ^c   Yan, Hai ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR OTX2; WNT PROTEIN;

ANAPLASTIC CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CARCINOGENICITY; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE FUNCTION; GENE NUMBER; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDULLOBLASTOMA; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CEREBELLAR NEOPLASMS; DISEASE PROGRESSION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HEDGEHOG PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MEDULLOBLASTOMA; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OTX TRANSCRIPTION FACTORS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 75149149855     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2331     Document Type: Article

References (43)

1. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61: 215-25; discussion 26-9.
2. Pietsch T, Taylor MD, Rutka JT. Molecular pathogenesis of childhood brain tumors. J Neurooncol 2004;70:203-15.
3. Zakhary R, Keles GE, Aldape K, Berger MS. Medulloblastoma and primitive neuroectodermal tumors. In: Kaye AH, Law ER, editors. Brain tumors: an encyclopedic approach. London: Churchill Livingstone; 2001, p. 605-15.
4. Packer RJ, Reddy A. New treatments in pediatric brain tumors. Curr Treat Options Neurol 2004;6:377-89.
5. Gajjar A, Hernan R, Kocak M, et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004;22:984-93.
6. Ray A, Ho M, Ma J, et al. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res 2004;10:7613-20.
7. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 2001;19:3470-6.
8. Xu W, Janss A, Packer RJ, Phillips P, Goldwein J, Moshang T, Jr. Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. Neuro Oncol 2004;6: 113-8.
9. Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A, Sainte-Rose C, Pierre-Kahn A, Hirsch JF. Medulloblastoma in childhood: progressive intellectual deterioration. Childs Nerv Syst 1990;6:60-5.
10. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JY, Tamayo P, Pomeroy SL. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 2004; 22:994-8.
11. Lee Y, Miller HL, Jensen P, et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003;63:5428-37.
12. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001;29:143-52.
13. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415:436-42.
14. Boon K, Eberhart CG, Riggins G. Genomic amplification of orthodenticle homolog 2 in medulloblastomas. Cancer Res 2005;65:703-7.
15. Di CH, Liao SH, Adamson DC, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all -trans-retinoic acid. Cancer Res 2005;65:919-24.
16. Yokota N, Mainprize TG, Taylor MD, et al. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 2004;23:3444-53.
17. Michiels EM, Oussoren E, Van Groenigen M, et al. Genes differentially expressed in medulloblastoma and fetal brain. Physiol Genomics 1999;1:83-91.
18. Simeone A, Puelles E, Acampora D. The Otx family. Curr Opin Genet Dev 2002;12:409-15.
19. Broccoli V, Boncinelli E, Wurst W. The caudal limit of Otx2 expression positions the isthmic organizer. Nature 1999;401:164-8.
20. Frantz GD, Weimann JM, Levin ME, McConnell SK. Otx1 and Otx2 define layers and regions in developing cerebral cortex and cerebellum. J Neurosci 1994;14:5725-40.
21. Matsuo I, Kuratani S, Kimura C, Takeda N, Aizawa S. Mouse Otx2 functions in the formation and patterning of rostral head. Genes Dev 1995;9:2646-58.
22. Ang SL, Jin O, Rhinn M, Daigle N, Stevenson L, Rossant J. A targeted mouse Otx2 mutation leads to severe defects in gastrulation and formation of axial mesoderm and to deletion of rostral brain. Development 1996;122:243-52.
23. Simeone A, Acampora D, Mallamaci A, et al. A vertebrate gene related to orthodenticle contains a homeodomain of the bicoid class and demarcates anterior neuroectoderm in the gastrulating mouse embryo. EMBO J 1993;12:2735-47.
24. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002;126:540-4.
25. McLendon RE, Rosenblum MK, Bigner DD, Russell DS, Rubinstein LJ. Russell and Rubinstein's pathology of tumors of the nervous system. 7th ed London: Hodder Arnold; 2006.
26. Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol 2003;13:376-85.
27. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009;41:465-72.
28. Northcott PA, Fernandez LA, Hagan JP, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 2009;69:3249-55.
29. Wang TL, Diaz LA, Jr., Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 2004;101:3089-94.
30. Kolligs FT, Hu G, Dang CV, Fearon ER. Neoplastic transformation of RK3E by mutant β-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 1999;19: 5696-706.
31. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12.
32. Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008;3: e3088.
33. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006;24:1924-31.
34. Briata P, Ilengo C, Bobola N, Corte G. Binding properties of the human homeodomain protein OTX2 to a DNA target sequence. FEBS Lett 1999;445:160-4.
35. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004;63:441-9.
36. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002;94:552-60.
37. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res 2006;66:673-81.
38. de Haas T, Oussoren E, Grajkowska W, et al. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol 2006;65:176-86.
39. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001;24:385-428.
40. Yang ZJ, Ellis T, Markant SL, et al. Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell 2008;14:135-45.
41. Schuller U, Heine VM, Mao J, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008;14:123-34.
42. Vernay B, Koch M, Vaccarino F, et al. Otx2 regulates subtype specification and neurogenesis in the midbrain. J Neurosci 2005;25: 4856-67.
43. Omodei D, Acampora D, Mancuso P, et al. Anterior-posterior graded response to Otx2 controls proliferation and differentiation of dopaminergic progenitors in the ventral mesencephalon. Development 2008; 135:3459-70.